Tag: Trial

Posted on

KaloBios shares tank on failed asthma drug trial – San Francisco Business Times (blog)

KaloBios shares tank on failed asthma drug trial
San Francisco Business Times (blog)
KaloBios (NASDAQ: KBIO), which has seen its stock price tumble since it raised $70 million in an initial public offering a year ago, will discontinue clinical development of the drug, called KB-003, in severe asthma. The monoclonal antibody was safe …
KaloBios to Stop KB003 Development for AsthmaZacks.com
KaloBios calls it quits on its asthma drug after a Phase II flopFierceBiotech
KaloBios Pharma pulls plug on asthma drug, shares plungeReuters
Wall Street Journal
all 31 news articles »

View full post on asthma – Google News

Posted on

UI Health leads trial to help kids with asthma – HealthCanal.com

UI Health leads trial to help kids with asthma
HealthCanal.com
The University of Illinois Hospital & Health Sciences System has been awarded a $4 million, three-year contract by the Patient-Centered Outcomes Research Institute to coordinate a multi-center trial to investigate treatments for uncontrolled asthma in …
National Asthma guidelines for PHCs launchedGulf Today

all 3 news articles »

View full post on asthma – Google News

Posted on

New clinical trial shows increased asthma control with FeNO-guided anti … – News-Medical.net

New clinical trial shows increased asthma control with FeNO-guided anti …
News-Medical.net
A total of 187 non-smoking asthma patients (18-64 years) with perennial allergy and on regular inhaled corticosteroid (ICS) treatment were recruited at 17 primary health care centres in Sweden, randomly assigned to two groups and followed for one year.
AEROCRINE AB : Aerocrine: First Primary Care Trial Supports FeNO-Guided …4-traders (press release)

all 3 news articles »

View full post on asthma – Google News

Posted on

AEROCRINE AB : Aerocrine: First Primary Care Trial Supports FeNO-Guided … – 4-traders (press release)

AEROCRINE AB : Aerocrine: First Primary Care Trial Supports FeNO-Guided …
4-traders (press release)
Aerocrine AB (STO:AERO-B) – A new randomised clinical trial shows lower incidence of asthma exacerbations and increased asthma control with Fractional exhaled Nitric Oxide (FeNO)-guided anti-inflammatory treatment. The study has been published on …

and more »

View full post on asthma – Google News

Posted on

Dynavax Technologies Corporation (DVAX): Dynavax Initiates Phase I Trial In … – Seeking Alpha

Dynavax Technologies Corporation (DVAX): Dynavax Initiates Phase I Trial In …
Seeking Alpha
After the close of the markets on Wednesday, October 9, 2013, Dynavax (DVAX) announced it will begin dosing patients in the first human trial in its asthma program. The trial, which is being conducted under a collaborative agreement with AstraZeneca …

View full post on asthma – Google News

Posted on

Dynavax starts Phase I trial of asthma treatment – San Francisco Business Times (blog)

Dynavax starts Phase I trial of asthma treatment
San Francisco Business Times (blog)
The Berkeley company (NASDAQ: DVAX) will enroll up to 45 people in this Phase I trial of AZD1419, an inhaled TLR9 agonist. These pioneering patients will all be healthy, and they'll get either the drug in ascending doses or a placebo. If all goes well, …
DYNAVAX TECHNOLOGIES CORPORATION : Dynavax Initiates First Human …4-traders (press release)
Dynavax Initiates First Human Trial in Asthma ProgramMENAFN.COM

all 3 news articles »

View full post on asthma – Google News

Posted on

Rigel drops asthma drug after trial fails, stock hits life-low – Reuters


The Denver Channel

Rigel drops asthma drug after trial fails, stock hits life-low
Reuters
(Reuters) – Rigel Pharmaceuticals Inc said it will stop developing its experimental asthma drug after the therapy failed in a mid-stage trial, sending its shares down as much as 17 percent to a life-low. The failure of the inhaled drug is the latest …
Rigel Shares Plunge After Asthma Drug Fails to Meet GoalsBloomberg
Rigel shares slide after another drug flops in PhII asthma studyFierceBiotech
Rigel Pharmaceuticals skids after asthma drug fails in studyThe Denver Channel
Wall Street Journal –PR Newswire (press release) –NASDAQ
all 30 news articles »

View full post on asthma – Google News